[go: up one dir, main page]

MA42665A - Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations - Google Patents

Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations

Info

Publication number
MA42665A
MA42665A MA042665A MA42665A MA42665A MA 42665 A MA42665 A MA 42665A MA 042665 A MA042665 A MA 042665A MA 42665 A MA42665 A MA 42665A MA 42665 A MA42665 A MA 42665A
Authority
MA
Morocco
Prior art keywords
diantibodies
binding
bispecific monovalent
bispecific
monovalent
Prior art date
Application number
MA042665A
Other languages
English (en)
Inventor
Ralph Alderson
Ezio Bonvini
Gurunadh Reddy Chichili
Ling Huang
Leslie S Johnson
Paul A Moore
Kalpana Shah
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MA42665A publication Critical patent/MA42665A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA042665A 2015-08-17 2016-08-12 Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations MA42665A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US201662280318P 2016-01-19 2016-01-19

Publications (1)

Publication Number Publication Date
MA42665A true MA42665A (fr) 2018-06-27

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042665A MA42665A (fr) 2015-08-17 2016-08-12 Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations

Country Status (21)

Country Link
US (1) US20190002563A1 (fr)
EP (1) EP3337507A4 (fr)
JP (1) JP2018523686A (fr)
KR (1) KR20180038045A (fr)
CN (1) CN107921130A (fr)
AU (1) AU2016307955A1 (fr)
CA (1) CA2995709A1 (fr)
CL (1) CL2018000422A1 (fr)
CO (1) CO2018001485A2 (fr)
CR (1) CR20180105A (fr)
EA (1) EA201890443A1 (fr)
EC (1) ECSP18011248A (fr)
HK (1) HK1249423A1 (fr)
IL (1) IL257562A (fr)
MA (1) MA42665A (fr)
MX (1) MX2018001954A (fr)
PE (1) PE20181066A1 (fr)
PH (1) PH12018500363A1 (fr)
TW (1) TW201718652A (fr)
WO (1) WO2017030926A1 (fr)
ZA (1) ZA201800955B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152235B1 (fr) * 2014-05-29 2021-08-25 MacroGenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
KR20170063755A (ko) 2014-09-26 2017-06-08 마크로제닉스, 인크. Cd19 및 cd3에 결합할 수 있는 이중-특이적 1가 디아바디, 및 그것의 사용
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR102771251B1 (ko) * 2017-09-08 2025-02-24 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
MX2020010638A (es) 2018-04-11 2021-01-08 Inhibrx Inc Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados.
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
WO2020077257A1 (fr) 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps pd-1 à domaine unique et compositions thérapeutiques associées
WO2020076970A1 (fr) 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps b7h3 à domaine unique et compositions thérapeutiques associées
CN112955471B (zh) * 2018-12-07 2022-11-22 江苏恒瑞医药股份有限公司 Cd3抗体及其药物用途
CN112969476B (zh) * 2018-12-07 2024-06-14 江苏恒瑞医药股份有限公司 多特异性蛋白分子
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (fr) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Anticorps ciblant et autres modulateurs de l'antigène cd276 et leurs utilisations
AU2020412595A1 (en) * 2019-12-23 2022-07-14 Macrogenics, Inc. Therapy for the treatment of cancer
EP4097129A1 (fr) 2020-01-29 2022-12-07 Inhibrx, Inc. Anticorps cd28 à domaine unique et constructions multivalentes et multispécifiques de ceux-ci
EP4032910A1 (fr) * 2021-01-22 2022-07-27 ETH Zurich Agent de liaison bispécifique qui se lie au cd3 et à un fluorophore
WO2022232392A2 (fr) * 2021-04-28 2022-11-03 Lyvgen Biopharma Holdings Limited Anticorps bi-spécifiques comprenant des molécules de liaison anti-b7h3
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
WO2023086772A1 (fr) 2021-11-12 2023-05-19 Xencor, Inc. Anticorps bispécifiques se liant à b7h3 et à nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
WO2025245264A1 (fr) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anticorps anti-b7-h3 et leurs méthodes d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2542256T (lt) * 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
HRP20190756T1 (hr) * 2011-05-21 2019-06-14 Macrogenics, Inc. Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (fr) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
HK1251475A1 (zh) * 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法

Also Published As

Publication number Publication date
MX2018001954A (es) 2018-11-09
CN107921130A (zh) 2018-04-17
EP3337507A1 (fr) 2018-06-27
AU2016307955A1 (en) 2018-03-08
IL257562A (en) 2018-04-30
WO2017030926A1 (fr) 2017-02-23
CO2018001485A2 (es) 2018-07-10
JP2018523686A (ja) 2018-08-23
PE20181066A1 (es) 2018-07-04
EP3337507A4 (fr) 2019-04-24
TW201718652A (zh) 2017-06-01
ECSP18011248A (es) 2018-04-30
CA2995709A1 (fr) 2017-02-23
US20190002563A1 (en) 2019-01-03
HK1249423A1 (zh) 2018-11-02
EA201890443A1 (ru) 2018-09-28
ZA201800955B (en) 2018-11-28
KR20180038045A (ko) 2018-04-13
CL2018000422A1 (es) 2018-08-10
CR20180105A (es) 2018-06-12
PH12018500363A1 (en) 2018-09-10

Similar Documents

Publication Publication Date Title
MA42665A (fr) Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations
CY2024026I1 (el) Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
IL258909A (en) Antibodies specifically binding pd-1 and their uses
MA47612A (fr) Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
IL256871B (en) Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
IL259834A (en) Heterodimeric antibodies that bind cd3 and psma
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
EP3377102A4 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
PL3035965T4 (pl) Dwuswoiste jednowartościowe diaciała zdolne do wiązania CD123 i CD3 oraz ich zastosowania
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
IL253358B (en) Human antibodies to ebola virus glycoprotein
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
SMT201600392B (it) Anticorpi bispecifici diretti contro cd3epsilon e bcma
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
IL244238B (en) Monovalent bispecific diabolites capable of binding to gpa33 and cd3 and their uses
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
EP3337486A4 (fr) Composés deutérés et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations